Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

LIFE | Atyr Pharma Inc

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	9.80%	Shs Outstand	57.05M	Perf Week	-1.86%
Market Cap	90.14M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	4.00%	Shs Float	51.46M	Perf Month	-10.73%
Income	-45.05M	PEG	-	EPS next Q	-0.24	Inst Own	63.65%	Short Float / Ratio	0.80% / 1.69	Perf Quarter	-26.85%
Sales	10.39M	P/S	8.68	EPS this Y	39.27%	Inst Trans	0.72%	Short Interest	0.41M	Perf Half Y	-24.76%
Book/sh	1.86	P/B	0.85	EPS next Y	-3.60%	ROA	-39.39%	Target Price	23.20	Perf Year	-42.34%
Cash/sh	1.90	P/C	0.83	EPS next 5Y	13.00%	ROE	-46.72%	52W Range	1.53 - 3.07	Perf YTD	-27.85%
Dividend	-	P/FCF	-	EPS past 5Y	42.86%	ROI	-37.37%	52W High	-48.53%	Beta	1.26
Dividend %	-	Quick Ratio	9.25	Sales past 5Y	455.50%	Gross Margin	76.39%	52W Low	3.27%	ATR	0.07
Employees	70	Current Ratio	9.25	Sales Q/Q	-	Oper. Margin	-460.11%	RSI (14)	35.38	Volatility	4.17% 4.01%
Optionable	Yes	Debt/Eq	0.14	EPS Q/Q	49.46%	Profit Margin	-433.80%	Rel Volume	0.40	Prev Close	1.59
Shortable	Yes	LT Debt/Eq	0.13	Earnings	Aug 09 AMC	Payout	-	Avg Volume	243.93K	Price	1.58
Recom	1.33	SMA20	-3.81%	SMA50	-13.04%	SMA200	-24.05%	Volume	98,578	Change	-0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform	$22
Sep-21-21	Initiated	Piper Sandler	Overweight	$19
May-10-21	Initiated	Laidlaw	Buy	$18
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy	$13
Mar-04-20	Initiated	ROTH Capital	Buy	$15
Mar-02-20	Initiated	Oppenheimer	Outperform	$8
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight	$7
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	JP Morgan	Overweight	$44
Jun-01-15	Initiated	Citigroup	Buy	$32

Show Previous Ratings

Sep-11-23 08:00AM	aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes (GlobeNewswire)
Aug-30-23 09:35AM	Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE) (Zacks)
Aug-24-23 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 05:30PM	Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:29PM	Atyr Pharma: Q2 Earnings Snapshot (AP Finance)
04:00PM	Loading…
04:00PM	aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Jul-20-23 07:30AM	aTyr Pharma, Inc. (NASDAQ:LIFE) is a favorite amongst institutional investors who own 56% (Simply Wall St.)
Jun-28-23 07:00AM	7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023 (InvestorPlace)
Jun-22-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Systemic Sclerosis (GlobeNewswire)
Jun-20-23 08:00AM	aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference (GlobeNewswire)
Jun-09-23 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-23 08:00AM	aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023) (GlobeNewswire)
May-25-23 08:00AM	aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 08:00AM	aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference (GlobeNewswire)
07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com)
08:06AM	Loading…
May-13-23 08:06AM	aTyr Pharma Independent Director Acquires 25% More Stock \ (Simply Wall St.)
May-11-23 04:00PM	aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-10-23 06:11AM	aTyr Pharma (NASDAQ:LIFE) investors are sitting on a loss of 89% if they invested five years ago (Simply Wall St.) +6.10%
May-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Atyr Pharma: Q1 Earnings Snapshot (AP Finance)
04:00PM	aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
May-07-23 04:00AM	3 Stocks and Cryptos With the Highest Potential Returns (InvestorPlace)
May-05-23 02:24PM	7 Hot Growth Stocks Poised to Triple in 2023 (InvestorPlace)
Apr-17-23 08:00AM	aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting (GlobeNewswire)
Mar-30-23 08:00AM	aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases (GlobeNewswire)
Mar-28-23 10:45AM	2 Strong Buy Penny Stocks With Over 200% Upside on the Horizon (TipRanks) +9.64%
Mar-23-23 07:10AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 08:00AM	aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution (GlobeNewswire)
Mar-20-23 08:00AM	aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies (GlobeNewswire)
Mar-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.18%
04:00PM	Loading…
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update (GlobeNewswire)
Mar-08-23 08:00AM	aTyr Pharma to Present at March Investor Conferences (GlobeNewswire)
Mar-02-23 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results (GlobeNewswire)
Mar-01-23 08:00AM	aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application (GlobeNewswire)
Feb-17-23 12:00PM	Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-10-23 05:21AM	With 37% stake, aTyr Pharma, Inc. (NASDAQ:LIFE) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-09-23 08:00AM	aTyr Pharma Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.56%
Feb-08-23 04:11PM	aTyr Pharma Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-06-23 08:00AM	aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd. (GlobeNewswire) +6.52%
Jan-31-23 08:00AM	aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference (GlobeNewswire)
Jan-19-23 08:00AM	aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis (GlobeNewswire)
Jan-18-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Sarcoidosis (GlobeNewswire)
Dec-29-22 06:59PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-15-22 08:00AM	aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment (GlobeNewswire)
Nov-18-22 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 05:15PM	Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:00PM	aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-09-22 08:00AM	aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST (GlobeNewswire)
Nov-03-22 08:02AM	aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-25-22 08:00AM	aTyr Pharma to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-11-22 08:00AM	aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets (GlobeNewswire)
Oct-04-22 08:00AM	aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (GlobeNewswire) +6.64%
Sep-29-22 08:00AM	aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies (GlobeNewswire)
Sep-27-22 08:00AM	aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis (GlobeNewswire)
Sep-16-22 08:35AM	Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire) -6.73%
Sep-13-22 08:00AM	aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) (GlobeNewswire)
Sep-12-22 08:35AM	Life Sciences Virtual Investor Conference Agenda Announced for September 15th (GlobeNewswire)
Sep-09-22 11:52AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
08:00AM	aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th (GlobeNewswire)
Sep-06-22 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022 (GlobeNewswire)
Sep-01-22 08:00AM	aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022 (GlobeNewswire)
Aug-15-22 04:00PM	aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
Aug-12-22 04:05PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-22 08:03AM	aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis (GlobeNewswire)
Aug-04-22 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-24-22 02:22PM	Bullish aTyr Pharma, Inc. (NASDAQ:LIFE) insiders filled their treasuries with US$2.1m worth of stock over last year (Simply Wall St.)
Jun-14-22 08:00AM	aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment (GlobeNewswire)
Jun-13-22 08:00AM	aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference (GlobeNewswire) -6.03%
Jun-01-22 08:00AM	aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 08:00AM	aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference (GlobeNewswire)
May-16-22 08:00AM	aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis (GlobeNewswire)
May-13-22 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-22 02:00PM	Is aTyr Pharma, Inc. (NASDAQ:LIFE) Popular Amongst Institutions? (Simply Wall St.)
08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences in May (GlobeNewswire)
May-09-22 05:15PM	Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.07%
04:00PM	aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
02:40AM	Love Hemp Group PLC Announces Update Regarding Trading Suspension (ACCESSWIRE)
May-02-22 08:00AM	aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results (GlobeNewswire)
Apr-14-22 12:14PM	aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod (Zacks)
Apr-13-22 08:00AM	aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis (GlobeNewswire) +7.38%
Apr-11-22 08:00AM	aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting (GlobeNewswire)
Apr-06-22 09:55AM	Does Atyr Pharma (LIFE) Have the Potential to Rally 236% as Wall Street Analysts Expect? (Zacks)
Apr-02-22 03:25PM	We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate (Simply Wall St.)
Apr-01-22 11:45AM	Love Hemp Group PLC Announces Result of General Meeting (ACCESSWIRE)
08:00AM	aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference (GlobeNewswire)
Mar-31-22 01:05PM	Love Hemp Group PLC Announces Interim Results (ACCESSWIRE)
Mar-25-22 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-22-22 08:48PM	Oppenheimer Predicts Over 90% Rally for These 2 Stocks (TipRanks)
Mar-21-22 10:00AM	Can Atyr Pharma (LIFE) Climb 266% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-17-22 12:00PM	Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know (Zacks) +6.88%
Mar-14-22 04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update (GlobeNewswire) -9.35%
Mar-10-22 08:03AM	aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis (GlobeNewswire)
Mar-08-22 04:35PM	aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-07-22 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2021 Financial Results (GlobeNewswire)
Mar-03-22 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Mar-01-22 05:25PM	NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-24-22 08:25AM	Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-23-22 08:00AM	aTyr Pharma to Participate in Panel at National Institutes of Health Rare Disease Day® (GlobeNewswire)
Feb-07-22 08:00AM	aTyr Pharma to Present at BIO CEO & Investor Conference (GlobeNewswire)

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shukla Sanjay	President and CEO	Jul 28	Buy	2.01	15,000	30,224	76,173	Aug 01 04:07 PM
SCHIMMEL PAUL	Director	May 10	Buy	2.25	200,000	450,000	313,023	May 11 09:00 AM
Broadfoot Jill Marie	Chief Financial Officer	Feb 06	Sale	2.36	1,566	3,696	15,460	Feb 06 07:00 PM
Shukla Sanjay	President and CEO	Nov 21	Buy	2.14	10,000	21,405	50,798	Nov 21 09:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIFE | Atyr Pharma Inc

Upgrade your FINVIZ experience